Marixino

Memantine, the active ingredient in Marixino, is a NMDA receptor antagonist presented as an oral formulation for oral use. It is indicated for the treatment of Alzheimer’s disease in adult patients, helping to improve cognition and functional abilities. GNH USA supplies Marixino as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Memantine acts on the glutamatergic pathway and is used in the management of Alzheimer’s disease. - Mild Alzheimer’s disease: may improve memory and daily functioning in early‑stage patients. - Moderate Alzheimer’s disease: helps maintain cognition and slows functional decline in mid‑stage disease. - Cognitive decline in Alzheimer’s disease: supports overall cognitive performance and daily activities.

Memantine is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Dizziness: transient light‑headedness, especially at treatment initiation. - Headache: mild to moderate intensity, often resolves with continued use. - Constipation: reduced bowel movements, may require dietary adjustment. - Nausea: occasional upset stomach, usually mild.

Serious or Rare Side Effects: - Severe skin reactions: such as Stevens‑Johnson syndrome, requiring immediate medical attention. - Hypersensitivity: rash, swelling, or anaphylaxis in rare cases. - Seizures: rare occurrence, particularly in patients with a seizure history. - Hallucinations or psychosis: uncommon neuropsychiatric events that need prompt evaluation.

Before initiating therapy, consider the following precautions. - Renal impairment: assess kidney function and adjust dose if necessary. - Hepatic impairment: monitor liver enzymes and consider dose modification. - History of seizures: use with caution and monitor for neurological changes. - Concomitant NMDA antagonists: avoid combined use to reduce risk of neurotoxicity. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Memantine may interact with several drug classes.

Major Interactions (Avoid): - Amantadine: additive central nervous system effects may increase confusion or dizziness. - Other NMDA antagonists: combined use can heighten neurotoxicity risk.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: may diminish memantine’s cognitive benefits. - Diuretics: can raise plasma memantine concentrations, requiring monitoring. - CNS depressants (e.g., benzodiazepines): may enhance sedation and dizziness.